Potassium Phosphates is a drug owned by Cmp Development Llc. It is protected by 1 US drug patent filed in 2020 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 19, 2039. Details of Potassium Phosphates's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10632150 | Potassium phosphates composition for injection |
Apr, 2039
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Potassium Phosphates's patents.
Latest Legal Activities on Potassium Phosphates's Patents
Given below is the list of recent legal activities going on the following patents of Potassium Phosphates.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Oct, 2023 | US10632150 |
| Recordation of Patent Grant Mailed Critical | 28 Apr, 2020 | US10632150 |
| Patent Issue Date Used in PTA Calculation Critical | 28 Apr, 2020 | US10632150 |
| Email Notification Critical | 24 Apr, 2020 | US10632150 |
| PG-Pub Issue Notification Critical | 23 Apr, 2020 | US10632150 |
| Application ready for PDX access by participating foreign offices Critical | 23 Apr, 2020 | US10632150 |
| Email Notification Critical | 09 Apr, 2020 | US10632150 |
| Issue Notification Mailed Critical | 08 Apr, 2020 | US10632150 |
| Dispatch to FDC | 25 Mar, 2020 | US10632150 |
| Application Is Considered Ready for Issue Critical | 25 Mar, 2020 | US10632150 |
US patents provide insights into the exclusivity only within the United States, but Potassium Phosphates is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Potassium Phosphates's family patents as well as insights into ongoing legal events on those patents.
Potassium Phosphates's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Potassium Phosphates's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 19, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Potassium Phosphates Generic API suppliers:
Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic is the generic name for the brand Potassium Phosphates. 4 different companies have already filed for the generic of Potassium Phosphates, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Potassium Phosphates's generic
About Potassium Phosphates
Potassium Phosphates is a drug owned by Cmp Development Llc. It is used for correcting hypophosphatemia in adults and pediatric patients 12 years of age and older. Potassium Phosphates uses Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic as an active ingredient. Potassium Phosphates was launched by Cmp Dev Llc in 2019.
Approval Date:
Potassium Phosphates was approved by FDA for market use on 19 September, 2019.
Active Ingredient:
Potassium Phosphates uses Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic as the active ingredient. Check out other Drugs and Companies using Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic ingredient
Treatment:
Potassium Phosphates is used for correcting hypophosphatemia in adults and pediatric patients 12 years of age and older.
Dosage:
Potassium Phosphates is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML) | SOLUTION | Discontinued | INTRAVENOUS |